Dimitri Grigoriadis - Neurocrine Biosciences Chief Officer
| N1BI34 Stock | 36.16 0.49 1.37% |
Executive
Dimitri Grigoriadis is Chief Officer of Neurocrine Biosciences
| Age | 65 |
| Phone | 858 617 7600 |
| Web | https://www.neurocrine.com |
Neurocrine Biosciences Management Efficiency
The company has return on total asset (ROA) of 0.0701 % which means that it generated a profit of $0.0701 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.1003 %, meaning that it generated $0.1003 on every $100 dollars invested by stockholders. Neurocrine Biosciences' management efficiency ratios could be used to measure how well Neurocrine Biosciences manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Celia Karam | Capital One Financial | 44 | |
| Noah Kotch | Credit Acceptance | 53 | |
| Ravi Mohan | Credit Acceptance | N/A | |
| Erin Kerber | Credit Acceptance | 44 | |
| John China | SVB Financial Group | 57 | |
| Matthew Cooper | Capital One Financial | 50 | |
| Arthur Smith | Credit Acceptance | 50 | |
| Daniel Beck | SVB Financial Group | 50 | |
| Laura Cushing | SVB Financial Group | N/A | |
| Daniel Ulatowski | Credit Acceptance | 51 | |
| Michelle Draper | SVB Financial Group | 55 | |
| Michael Zuckert | SVB Financial Group | 64 | |
| Marc Cadieux | SVB Financial Group | 56 | |
| Andrew Rostami | Credit Acceptance | N/A | |
| Meghan OLeary | SVB Financial Group | N/A | |
| Douglas Busk | Credit Acceptance | 63 | |
| Sanjiv Yajnik | Capital One Financial | 66 | |
| Karen Hon | SVB Financial Group | 45 | |
| Philip Cox | SVB Financial Group | 56 | |
| Michael Wassmer | Capital One Financial | 53 | |
| Robert Alexander | Capital One Financial | 58 | |
Management Performance
| Return On Equity | 0.1 | |||
| Return On Asset | 0.0701 |
Neurocrine Biosciences Leadership Team
Elected by the shareholders, the Neurocrine Biosciences' board of directors comprises two types of representatives: Neurocrine Biosciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Neurocrine. The board's role is to monitor Neurocrine Biosciences' management team and ensure that shareholders' interests are well served. Neurocrine Biosciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Neurocrine Biosciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Julie Cooke, Chief Officer | ||
| Matthew Abernethy, Chief Officer | ||
| Jane Sorensen, Head Relations | ||
| Eiry MD, Chief Officer | ||
| Eric Benevich, Chief Officer | ||
| Darin Lippoldt, Chief Sec | ||
| Jude Onyia, Chief Officer | ||
| Kevin Gorman, CEO Director | ||
| Dimitri Grigoriadis, Chief Officer | ||
| Kyle Gano, Chief Officer |
Neurocrine Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Neurocrine Biosciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.1 | |||
| Return On Asset | 0.0701 | |||
| Profit Margin | 0.10 % | |||
| Operating Margin | 0.17 % | |||
| Current Valuation | 58.19 B | |||
| Shares Outstanding | 1.93 B | |||
| Price To Book | 7.33 X | |||
| Price To Sales | 44.39 X | |||
| Revenue | 1.13 B | |||
| Gross Profit | 1 B |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Information and Resources on Investing in Neurocrine Stock
When determining whether Neurocrine Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Neurocrine Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Neurocrine Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Neurocrine Biosciences Stock:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Neurocrine Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For information on how to trade Neurocrine Stock refer to our How to Trade Neurocrine Stock guide.You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.